Vendor Intelligence Report: Rhome Research

Executive summary

Across 4 Finnrick lab tests, Rhome Research has 4 pass / 0 fail — an overall pass rate of 100%. That headline is favorable but narrow: Finnrick coverage currently spans only BPC-157 and Retatrutide, with Retatrutide the more convincing product signal and BPC-157 passing without earning the same confidence tier. The full report shows why the rating changes under stricter grading, rather than treating pass/fail as a vendor-wide clean bill.

Rhome looks like a brand-new gray-market storefront, not a long-established lab operation. The domain was created in February 2026, the Wayback Machine had no captures, and the corporate trail points to a Wyoming LLC using a Sheridan mail-forwarding address while the public operator signal runs through Colorado. A LinkedIn-linked operator attribution is unusually clear for this sector, but the disclosed background is mortgage, insurance, fitness, and military service — not chemistry, compounding, or analytical QA.

The most important buyer caveat is the COA trail. Peptigrity attributes nine Rhome tests to Freedom Diagnostics, yet a Freedom Diagnostics company-name search surfaced only one Rhome COA. That may have a benign indexing explanation, but buyers need accession-level verification. External batch records also create product-specific splits: Retatrutide looks comparatively strong, while MOTS-C conflicts with the vendor’s 99%+ release standard and GHK-Cu shows a material label-quantity shortfall.

Rhome is therefore not a simple safe/unsafe read. It is a young vendor with promising Retatrutide data, thinner BPC-157 confidence by rating, weak public reputation depth, low-recourse payment incentives including Zelle, and GLP-1 regulatory continuity exposure despite no Rhome-specific enforcement action found.

Inside the full report:

• Appendix A Finnrick laboratory data with per-product pass/fail rates and methodology-divergence charts for BPC-157 and Retatrutide
• Domain, DNS, WHOIS, and Wayback timeline showing the February 2026 launch footprint
• Wyoming, Delaware, and operator-attribution exhibits tying the public company trail to Zachary Streva
• Freedom Diagnostics and Peptigrity COA reconciliation, including the one-search-result discrepancy
• Batch-content analysis for MOTS-C, GHK-Cu, GSH, and other external test records
• Payment-rail and regulatory-risk review covering Zelle, crypto, cards, and GLP-1 catalog exposure

Risk assessment

• COA verification risk — high: Peptigrity attributes nine Freedom Diagnostics tests to Rhome, but a Freedom Diagnostics company-name search returned only one Rhome COA.
• Product-specific batch-content risk — high: External records show GHK-Cu at 42.76 mg versus 50 mg label and MOTS-C at 98.82% despite Rhome’s 99%+ release standard; Finnrick Retatrutide and BPC-157 samples passed.
• Regulatory disruption risk for GLP-1 products — high: Rhome references Retatrutide, Semaglutide, and Tirzepatide; FDA enforcement patterns against comparable peptide vendors create continuity risk despite no Rhome-specific action found.
• New-vendor and operational-transparency risk — medium: Domain registered February 12, 2026; zero Wayback captures; Wyoming registered-agent address; no public facility, manufacturer, or scientific quality lead disclosed.
• Buyer recourse and payment-rail risk — medium: Rhome accepts or discusses Zelle, crypto, ACH/wire, and cards; a Zelle discount incentivizes a low-recourse rail even though card payment offers better dispute protection.